- Home
- INVE vs QNCX Comparison
INVE vs QNCX Comparison
Compare INVE & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | QNCX |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 167.0M |
| IPO Year | 1997 | 2019 |
Fundamental Metrics
Financial Performance| Metric | INVE | QNCX |
|---|---|---|
| Price | $3.65 | $0.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | $5.50 | ★ $10.00 |
| AVG Volume (30 Days) | 37.7K | ★ 33.4M |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1182.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $2.86 | $0.09 |
| 52 Week High | $4.07 | $4.55 |
Technical Indicators
Market Signals| Indicator | INVE | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 27.89 |
| Support Level | $3.25 | $0.09 |
| Resistance Level | $3.84 | $0.98 |
| Average True Range (ATR) | 0.19 | 0.01 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 64.30 | 19.86 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.